As the most frequently identified ER in 26 cancers (Figure S1A), TP53 mutation was involved in the ERBB signalling and ligand–receptor pairs correlated with chemokines, e.g. L1CAM‐ERBB2 and CCL8‐CCR3 (Figure 1C). This evidence concerns the gene EGFR and cancer.